针对神经退行性疾病的橄核酸治疗药物
1University High School, Irvine, CA, USA.
概括
新的寡核酸技术,如纳米粒子传递和C16结合,正在为神经退行性疾病提供小干扰RNA (siRNA) 和反感性寡核酸 (ASO) 疗法. 这些进步针对神经组织,为阿尔茨海默氏症等疾病提供希望.
科学领域:
- 生物技术是生物技术.
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 寡核酸,包括小干扰RNA (siRNA) 和反感性寡核酸 (ASO),在治疗具有有限选择的慢性疾病方面表现有前途.
- 目前的输送方法对肝组织有效,但在到达肝外组织,特别是神经组织方面面临挑战.
研究的目的:
- 审查最近在寡核酸输送技术的进步.
- 探索这些技术在治疗神经退行性疾病方面的潜力.
主要方法:
- 对寡核酸的纳米粒子输送系统的审查.
- 讨论局部施用策略,以加强组织向.
- 分析2'-O-hexadecyl (C16) -对改善寡核酸性质的结合.
- 对神经退行性疾病应用的临床转化因子的检查.
主要成果:
- 纳米粒子,局部施用和C16结合方法显示出扩大对神经组织的寡核酸适用性的潜力.
- 这些技术可以在中枢神经系统中克服siRNA和ASO疗法的输送障碍.
结论:
- 对于开发神经退行性疾病的新疗法而言,寡核酸输送方面的进展至关重要.
- 成功的临床转化需要解决与神经学应用的改性或工程性寡核酸相关的特定挑战.
相关概念视频
Alzheimer's Disease: Treatment
128
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
128
Parkinson's Disease: Overview
308
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
308
siRNA - Small Interfering RNAs
16.3K
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
16.3K
Drugs Affecting Neurotransmitter Synthesis
1.2K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.2K
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
85
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
85
Alzheimer's Disease: Overview
315
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
315


